Edition:
United States

BioLine RX Ltd (BLRX.OQ)

BLRX.OQ on NASDAQ Stock Exchange Capital Market

0.92USD
25 May 2018
Change (% chg)

$0.02 (+2.21%)
Prev Close
$0.90
Open
$0.94
Day's High
$0.94
Day's Low
$0.90
Volume
43,090
Avg. Vol
43,019
52-wk High
$1.34
52-wk Low
$0.78

Chart for

About

No overview information found for .
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  BLRX.OQ Industry Sector
P/E (TTM): -- 243.17 32.94
EPS (TTM): -- -- --
ROI: -- -7.30 12.79
ROE: -- -10.05 14.67

BRIEF-BioLineRx Reports Qtrly Loss Per Share $0.06

* QTRLY LOSS PER ORDINARY SHARE BASIC AND DILUTED $0.06 Source text for Eikon: Further company coverage:

May 22 2018

BRIEF-Biolinerx To Present Overall Survival Data At Eha From Phase 2A Study Of Bl-8040 In R/R Aml Patients

* BIOLINERX TO PRESENT OVERALL SURVIVAL DATA AT EHA FROM PHASE 2A STUDY OF BL-8040 IN R/R AML PATIENTS

May 17 2018

BRIEF-Biolinerx Announces Grant Of European Patent Covering Use Of Bl-8040 With Cytarabine

* BIOLINERX ANNOUNCES GRANT OF EUROPEAN PATENT COVERING USE OF BL-8040 WITH CYTARABINE FOR TREATING ACUTE MYELOID LEUKEMIA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

May 16 2018

BRIEF-BioLineRx Announces Notice of Allowance From USPTO for Patent Covering Immunotherapy for Treating Solid Tumors

* BIOLINERX ANNOUNCES NOTICE OF ALLOWANCE FROM USPTO FOR PATENT COVERING AGI-134 - A NOVEL IMMUNOTHERAPY FOR TREATING SOLID TUMORS

Mar 26 2018

BRIEF-Biolinerx Reports Year End 2017 Financial Results

* BIOLINE RX LTD - COMPANY HELD $49.5 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM BANK DEPOSITS AS OF DECEMBER 31, 2017 Source text for Eikon: Further company coverage:

Mar 06 2018

BRIEF-Biolinerx Announces Partial Monotherapy Results From Phase 2A Combat Study In Pancreatic Cancer

* BIOLINERX ANNOUNCES PARTIAL MONOTHERAPY RESULTS FROM PHASE 2A COMBAT STUDY IN PANCREATIC CANCER

Jan 17 2018

BRIEF-Bioline Rx Ltd Files For Mixed Shelf Of Up To $150 Million

* BIOLINE RX LTD FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Source text (http://bit.ly/2lcDvcH) Further company coverage:

Dec 28 2017

InVivo to open crop input unit to outside investors

PARIS, Dec 19 French agricultural group InVivo said on Tuesday that it plans to raise 50 million euros ($59 million) for its Bioline division, which develops crop inputs such as seeds and pesticides, by bringing in outside investors.

Dec 19 2017

BRIEF-BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML

* BIOLINERX REPORTS OVERALL SURVIVAL RESULTS FROM LONG-TERM FOLLOW-UP OF PHASE 2A TRIAL IN R/R AML

Dec 04 2017

Earnings vs. Estimates

No consensus analysis data available.